Harvard Apparatus Regenerative Technology Secures $5M to Continue Clinical Trial -

Harvard Apparatus Regenerative Technology secures $5M from a new investor to continue clinical trials for its organ regeneration technology, focusing on the HRGN Esophageal Implant for treating esophageal damage in cancer or injury patients, with potential expansion to pediatric cases.